Press release
ChemoCentryx, Inc. (NASDAQ: CCXI) Investor Notice: Update in Lawsuit announced
A lawsuit for certain investors in ChemoCentryx, Inc. (NASDAQ: CCXI) is pending.
Investors who are current long term investors in ChemoCentryx, Inc. (NASDAQ: CCXI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On May 5, 2021, a lawsuit was filed against ChemoCentryx, Inc over alleged securities laws violations. The plaintiff alleged that between November 26, 2019 and May 3, 2021, the defendants made false and/or misleading statements and/or failed to disclose that the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis, that the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan, that these issues presented a substantial concern regarding the viability of ChemoCentryx's NDA for avacopan for the treatment of ANCA-associated vasculitis, and that as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
On March 28, 2022, an amended consolidated complaint was filed.
Those who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ChemoCentryx, Inc. (NASDAQ: CCXI) Investor Notice: Update in Lawsuit announced here
News-ID: 2606576 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for ChemoCentryx
Investigation announced for Long-Term Investors in shares of ChemoCentryx, Inc. …
An investigation was announced for current long-term investors in shares of ChemoCentryx, Inc. (NASDAQ: CCXI) concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc.
Investors who are current long term investors in ChemoCentryx, Inc. (NASDAQ: CCXI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Investigation announced for Investors in shares of ChemoCentryx, Inc. (NASDAQ: C …
An investigation was announced concerning potential securities laws violations by ChemoCentryx, Inc. in connection with certain financial statements.
Investors who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) concerning whether a series of statements…
Investigation announced for Long-Term Investors in ChemoCentryx, Inc. (NASDAQ: C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc..
Investors who are current long term investors in ChemoCentryx, Inc. (NASDAQ: CCXI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NASDAQ: CCXI stocks follows a lawsuit filed against ChemoCentryx, Inc. over alleged securities laws…
Lawsuit filed for Investors in shares of ChemoCentryx, Inc. (NASDAQ: CCXI)
An investor, who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI), filed a lawsuit over alleged violations of Federal Securities Laws by ChemoCentryx, Inc.
Investors who purchased shares of ChemoCentryx, Inc. (NASDAQ: CCXI) have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2021. NASDAQ: CCXI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Mountain View, CA based ChemoCentryx, Inc., a…
Gout Therapeutics Market - Notable Growth Highlights 2025 | GlaxoSmithKline, Che …
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
Global C5a Anaphylatoxin Chemotactic Receptor 1 Market 2019 By AFFiRiS AG, Chemo …
The trending C5a Anaphylatoxin Chemotactic Receptor 1 report represents a comprehensive study of the global C5a Anaphylatoxin Chemotactic Receptor 1 market. It includes the growth rate of the global C5a Anaphylatoxin Chemotactic Receptor 1 market for the estimated period. The global report summarizes by providing the estimated development of the C5a Anaphylatoxin Chemotactic Receptor 1 market in the upcoming period. It also highlights the key factors for the development of…
